Table 2. Clinical characteristics of all patients with or without CI.
| Variables | CI (n = 41) | Non-CI (n = 54) | P-value |
| Mean follow-up period, days | 775 ± 495 | 1493 ± 785 | < 0.05 |
| Age, yrs | 85.2 ± 3.4 | 84.3 ± 3.1 | NS |
| Male sex | 23 (52%) | 32 (57%) | NS |
| BMI, kg/m2 | 23.2 ± 4.0 | 22.4 ± 3.6 | NS |
| Emergent PCI | 20 (45%) | 21 (37%) | NS |
| Prevalence of CHF on admission | 20 (45%) | 16 (29%) | NS |
| Comorbidity | |||
| Cardiac disease | 11 (39%) | 7 (18%) | NS |
| AF | 6 (15%) | 4 (7%) | NS |
| Conduction disturbance | 0 (0%) | 3 (6%) | NS |
| IHD | 0 (0%) | 2 (4%) | NS |
| Chronic heart failure | 6 (15%) | 2 (4%) | NS |
| Cerebrovascular disease | 5 (11%) | 4 (4%) | NS |
| Respiratory disease | 2 (4%) | 5 (9%) | NS |
| Malignant disease | 1 (2%) | 1 (2%) | NS |
| Major bleeding | 2 (4%) | 4 (4%) | NS |
| Hypertension | 33 (75%) | 44 (78%) | NS |
| Diabetes | 14 (32%) | 19 (36%) | NS |
| Chronic kidney disease | 23 (57%) | 24 (44%) | |
| Prevalence of physical disability on admission | 20 (50%) | 13 (24%) | < 0.05 |
| Dyslipidemia | 22 (50%) | 42 (75%) | < 0.05 |
| Laboratory data | |||
| Hemoglobin, g/dL | 12.3 ± 1.82 | 12.5 ± 1.69 | NS |
| Lymphocyte subset, % | 21.1 ± 11.1 | 23.5 ± 8.0 | NS |
| Albumin, g/mL | 3.76 ± 0.44 | 3.84 ± 0.53 | NS |
| eGFR, mL/min·1.73 m2 | 56 ± 18.4 | 61.3 ± 21.6 | NS |
| BNP on admission, pg/mL | 402 ± 528 | 277 ± 544 | NS |
| BNP on chronic phase, pg/mL | 426 ± 870 | 105 ± 115 | < 0.05 |
| Serum Na, mEq/L | 140 ± 4.56 | 139 ± 4.23 | NS |
| Cardiac function on admission | |||
| LVEF, % | 55 ± 1.9 | 61 ± 10.7 | < 0.05 |
| LAD, mm | 43 ± 8.4 | 42 ± 6.4 | NS |
| E/A | 0.89 ± 0.52 | 0.71 ± 0.24 | NS |
| LVH (IVS + PW > 21 mm) | 8 (18%) | 8 (14%) | NS |
| Cardiac function at the chronic phase | |||
| LVEF, % | 56 ± 12.9 | 63 ± 9.7 | < 0.05 |
| LAD, mm | 44.3 ± 7.07 | 41 ± 6.8 | NS |
| E/A | 0.69 ± 0.24 | 0.72 ± 0.29 | NS |
| LVH (IVS + PW > 21 mm) | 8 (18%) | 8 (14%) | NS |
| Medication | |||
| Antiplatelet | 42 (95%) | 54 (98%) | NS |
| ACE/ARB | 29 (66%) | 40 (71%) | NS |
| Diuretics | 15 (34%) | 15 (26%) | NS |
| Beta blocker | 24 (54%) | 28 (50%) | NS |
| Anti-aldosterone agent | 10 (22%) | 8 (14%) | NS |
| Statin | 28 (52%) | 42 (75%) | NS |
Data are presented as means ± SD or n (%). ACE: angiotensin-converting enzyme; AF: atrial fibrillation; ARB: angiotensin II receptor blocker; BMI: body mass index; BNP: brain natriuretic peptide; CHF: congestive heart failure; CI: cognitive impairment; eGFR: estimated glomerular filtration rate; IHD: ischemic heart disease; IVS: interventricular septum; LAD: left atrial dimension; LVEF: left ventricular ejection fraction; LVH: left ventricular hypertrophy; NS: no significance; PCI: percutaneous coronary intervention; PW: posterior wall.